Sunovion Pharmaceuticals Inc - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Summary

Sunovion Pharmaceuticals Inc (Sunovion), a subsidiary of Sumitomo Dainippon Pharma Co Ltd, is a research-based pharmaceutical company. It discovers, develops and commercializes therapeutic products that focus on the treatment of central nervous system and respiratory disorders. Its product portfolio includes eslicarbazepine acetate tablets, lurasidone HCl tablets, eszopiclone tablets, levalbuterol HCl inhalation solution, levalbuterol tartrate inhalation aerosol, arformoterol tartrate inhalation solution, ciclesonide nasal spray, ciclesonide inhalation aerosol and ciclesonide nasal aerosol. The existing product portfolio and the pipeline candidates are targeted for treating patients of epilepsy, anxiety, depression, asthma, pain, allergic rhinitis and chronic obstructive pulmonary diseases. Sunovions major customers include medical institutions, hospitals and general public. Sunovion is headquartered in Marlborough, Massachusetts, the US.

Sunovion Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

it derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.



List of Tables 5
List of Figures 5
Sunovion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Sunovion Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Sunovion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Sunovion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Sunovion Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Sunovion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Sunovion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Matrizyme Pharma Raises USD9 Million in Financing 13
Elevation Pharma Secures US$30 Million In Series B Financing 14
Private Equity 16
Orbimed Advisors Acquires Additional 3.17% Stake in Cynapsus Therapeutics for USD6.3 Million 16
Partnerships 17
ex scientia Enters into Research Agreement with Sunovion Pharma 17
Sunovion Pharma Enters Into Agreement With Afraxis To Discover CNS Drugs 18
PsychoGenics Extends Drug Discovery Agreement with Sunovion Pharma 19
Prasco Labs Enters into Distribution Agreement with Sunovion Pharma for Xopenex 20
Licensing Agreements 21
Angelini Enters into Licensing and Distribution Agreement with Sunovion Pharma 21
Sunovion Pharma Enters into Licensing Agreement with Novartis 22
Cynapsus Therapeutics Enters into Licensing Agreement with MonoSol Rx 23
Equity Offering 24
Cynapsus Therapeutics Raises USD72.5 Million in Public Offering of Shares 24
Cynapsus Therapeutics Raises USD16.6 Million in Private Placement of Shares 26
Cynapsus Therapeutics Completes Public Offering Of Units For US$22.8 Million 28
Cynapsus Therapeutics Completes Second Tranche Of Private Placement Of Units For US$1.3 Million 29
Cynapsus Therapeutics Completes Private Placement Of Units For US$1 Million 31
Cynapsus Therapeutics Completes Private Placement Of Units For US$0.2 Million 32
Cynapsus Therapeutics Completes Private Placement Of Units For US$0.1 Million 33
Debt Offering 34
Cynapsus Therapeutics Completes Additional Public Offering Of Series E Debentures Due 2013 For US$1.1 Million 34
Asset Transactions 36
Sunovion Pharma to Divest US Rights of Ciclesonide Products to Covis Pharma 36
Akorn Acquires Xopenex Inhalation Solution from Sunovion Pharma for USD45 Million 37
Acquisition 38
Sunovion Pharma Acquires Cynapsus Therapeutics for up to USD635 Million 38
Sunovion Pharma Completes Acquisition Of Elevation Pharma For Up To US$430 Million 40
Sunovion Pharmaceuticals Inc - Key Competitors 42
Sunovion Pharmaceuticals Inc - Key Employees 43
Sunovion Pharmaceuticals Inc - Locations And Subsidiaries 44
Head Office 44
Other Locations & Subsidiaries 44
Recent Developments 45
Product News 45
09/14/2017: Sunovion to Present Data on Dasotraline at the 2017 Psych Congress 45
05/23/2017: Sunovion Announces Positive Results from Pivotal Study Evaluating Novel Drug Candidate Dasotraline in Adults with Binge Eating Disorder at Annual American Psychiatric Association Meeting 46
05/16/2017: Sunovion to Present Data on Dasotraline at Annual American Psychiatric Association Meeting Showcase 48
05/02/2018: Sunovion to Present Data on dasotraline at the 2018 American Psychiatric Association Annual Meeting 49
01/14/2017: Sunovion Announces Pivotal Study Results for Novel Drug Candidate Dasotraline Demonstrating Significantly Improved Attention Deficit Hyperactivity Disorder Symptoms in Children Compared to Placebo 50
Product Approvals 51
Mar 30, 2018: Sunovion Submits New Drug Application to the FDA for Apomorphine Sublingual Film (APL-130277) for the Treatment of OFF Episodes Associated with Parkinsons Disease 51
Nov 10, 2017: Sunovion Announces FDA Acceptance for Review of New Drug Application for Dasotraline for the Treatment of ADHD 52
Aug 31, 2017: Sunovion Submits New Drug Application for Dasotraline to the FDA for the Treatment of Patients with ADHD 53
Jun 12, 2017: PsychoGenics Achieves a Milestone in Drug Discovery Collaboration with Sunovion 54
Clinical Trials 55
Jan 29, 2018: Sunovion Announces Positive Topline Results from Pivotal Study of Apomorphine Sublingual Film (APL-130277) in Patients with Parkinsons Disease 55
Apr 21, 2017: Sunovion Announces Positive Results from Pivotal Study Evaluating Novel Drug Candidate Dasotraline in Children with ADHD 57
Apr 12, 2017: Sumitomo Dainippon Pharma Announces Positive Topline Results from a Phase 3 Study of Novel Drug Candidate Dasotraline Being Evaluated in the Treatment of Children with Attention Deficit Hyperactivity Disorder 59
Jan 13, 2017: Sunovion Announces Top-line Results from Studies Evaluating Dasotraline in Adults with Binge Eating Disorder and Attention Deficit Hyperactivity Disorder 60
Appendix 62
Methodology 62
About GlobalData 62
Contact Us 62
Disclaimer 62

List Of Tables


Sunovion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2
Sunovion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Sunovion Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Sunovion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Sunovion Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Sunovion Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Sunovion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Matrizyme Pharma Raises USD9 Million in Financing 13
Elevation Pharma Secures US$30 Million In Series B Financing 14
Orbimed Advisors Acquires Additional 3.17% Stake in Cynapsus Therapeutics for USD6.3 Million 16
ex scientia Enters into Research Agreement with Sunovion Pharma 17
Sunovion Pharma Enters Into Agreement With Afraxis To Discover CNS Drugs 18
PsychoGenics Extends Drug Discovery Agreement with Sunovion Pharma 19
Prasco Labs Enters into Distribution Agreement with Sunovion Pharma for Xopenex 20
Angelini Enters into Licensing and Distribution Agreement with Sunovion Pharma 21
Sunovion Pharma Enters into Licensing Agreement with Novartis 22
Cynapsus Therapeutics Enters into Licensing Agreement with MonoSol Rx 23
Cynapsus Therapeutics Raises USD72.5 Million in Public Offering of Shares 24
Cynapsus Therapeutics Raises USD16.6 Million in Private Placement of Shares 26
Cynapsus Therapeutics Completes Public Offering Of Units For US$22.8 Million 28
Cynapsus Therapeutics Completes Second Tranche Of Private Placement Of Units For US$1.3 Million 29
Cynapsus Therapeutics Completes Private Placement Of Units For US$1 Million 31
Cynapsus Therapeutics Completes Private Placement Of Units For US$0.2 Million 32
Cynapsus Therapeutics Completes Private Placement Of Units For US$0.1 Million 33
Cynapsus Therapeutics Completes Additional Public Offering Of Series E Debentures Due 2013 For US$1.1 Million 34
Sunovion Pharma to Divest US Rights of Ciclesonide Products to Covis Pharma 36
Akorn Acquires Xopenex Inhalation Solution from Sunovion Pharma for USD45 Million 37
Sunovion Pharma Acquires Cynapsus Therapeutics for up to USD635 Million 38
Sunovion Pharma Completes Acquisition Of Elevation Pharma For Up To US$430 Million 40
Sunovion Pharmaceuticals Inc, Key Competitors 42
Sunovion Pharmaceuticals Inc, Key Employees 43
Sunovion Pharmaceuticals Inc, Other Locations 44
Sunovion Pharmaceuticals Inc, Subsidiaries 44

List Of Figures


Sunovion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Sunovion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Sunovion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Sunovion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Sunovion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Sunovion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Sunovion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Sunovion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Sunovion Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

Sunovion Pharmaceuticals Inc - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Sunovion Pharmaceuticals Inc (Sunovion), a subsidiary of Sumitomo Dainippon Pharma Co Ltd, is a research-based pharmaceutical company. It discovers, develops and commercializes therapeutic products that focus on the treatment of

USD 250 View Report

Sunovion Pharmaceuticals Inc Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Sunovion Pharmaceuticals Inc Company Profile is a detailed strategic and analytical report on Sunovion Pharmaceuticals Inc. The 2018 version of the report offers detailed insights into the companys strategies, developments,

USD 200 View Report

NeuroBo Pharmaceuticals Inc (NRBO) - Financial and Strategic SWOT Analysis Review

NeuroBo Pharmaceuticals Inc (NRBO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled to

USD 125 View Report

EyePoint Pharmaceuticals Inc (PSDV) - Financial and Strategic SWOT Analysis Review

EyePoint Pharmaceuticals Inc (EyePoint), formerly pSivida Corp, is a biopharmaceutical company that provides development of miniaturized, sustained-release drug delivery products and technologies. The company offers products such as iluvien, retisert

USD 300 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available